TAK
Takeda Pharmaceutical Co Ltd (ADR)

3,709
Mkt Cap
$59.24B
Volume
2.15M
52W High
$18.82
52W Low
$12.99
PE Ratio
75.67
TAK Fundamentals
Price
$18.75
Prev Close
$18.53
Open
$18.55
50D MA
$16.80
Beta
0.24
Avg. Volume
3.44M
EPS (Annual)
$0.2242
P/B
1.21
Rev/Employee
$633,289.19
$79,201.26
Loading...
Loading...
News
all
press releases
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus
Denali posts narrower-than-expected Q4 loss as FDA extends review of tividenofusp alfa, with $966M cash backing pipeline advances and no Q4 revenues.
Zacks·3d ago
News Placeholder
More News
News Placeholder
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity PR Newswire NEW YORK, Feb. 24, 2026...
PR Newswire·6d ago
News Placeholder
Takeda Pharmaceutical (NYSE:TAK) Sets New 52-Week High - Here's Why
Takeda Pharmaceutical (NYSE:TAK) Sets New 52-Week High - What's Next...
MarketBeat·6d ago
News Placeholder
Positive Phase 3 Data Demonstrate Potential for ENTYVIO (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO (vedolizumab) can offer the possibility of clinical remission for...
Business Wire·10d ago
News Placeholder
Takeda Pharmaceutical (NYSE:TAK) Reaches New 12-Month High - Here's What Happened
Takeda Pharmaceutical (NYSE:TAK) Reaches New 12-Month High - What's Next...
MarketBeat·11d ago
News Placeholder
Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?
KROS investors eye pipeline updates as rinvatercept advances in DMD and Takeda-backed elritercept hits milestones ahead of Q4 results.
Zacks·12d ago
News Placeholder
ABC Arbitrage SA Invests $8.37 Million in Takeda Pharmaceutical Co. $TAK
ABC Arbitrage SA acquired a new position in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and...
MarketBeat·19d ago
News Placeholder
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takedas Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the...
Business Wire·20d ago
News Placeholder
Takeda Pharmaceutical Co. $TAK Shares Sold by Federated Hermes Inc.
Federated Hermes Inc. lessened its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 25.4% in the 3rd quarter, according to its most recent filing with the Securities...
MarketBeat·27d ago
News Placeholder
Takeda Pharmaceutical (NYSE:TAK) Posts Earnings Results, Misses Estimates By $0.07 EPS
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) posted its earnings results on Thursday. The company reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates...
MarketBeat·29d ago
<
1
2
...
>

Latest TAK News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.